Search Result

Results for "

anti-inflammatory efficacies

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (2) Bacterial (6) Calcium Channel (2) Cannabinoid Receptor (3) Cathepsin (1) COX (4) Cyclic GMP-AMP Synthase (1) Drug Metabolite (1) Endogenous Metabolite (2) Epigenetic Reader Domain (1) Epoxide Hydrolase (2) FLAP (1) Fungal (1) GABA Receptor (2) Glucocorticoid Receptor (1) Glutathione S-transferase (1) HDAC (1) Histamine Receptor (3) HSP (2) Influenza Virus (1) Interleukin Related (2) Isotope-Labeled Compounds (1) JAK (1) Keap1-Nrf2 (1) LPL Receptor (1) LXR (1) Melanocortin Receptor (1) mTOR (1) NF-κB (7) NO Synthase (2) P-glycoprotein (2) p38 MAPK (1) PARP (1) Phosphodiesterase (PDE) (1) Phospholipase (1) PI3K (1) Potassium Channel (2) PPAR (6) Reactive Oxygen Species (1) ROR (1) Sodium Channel (2) TGF-beta/Smad (1) Toll-like Receptor (TLR) (3) Transmembrane Glycoprotein (1) Trk Receptor (1) TRP Channel (2) VD/VDR (1) VEGFR (1)
By Research Areas:	Cancer (17) Cardiovascular Disease (2) Endocrinology (1) Infection (6) Inflammation/Immunology (55) Metabolic Disease (4) Neurological Disease (9)

By Targets:

Antibiotic (1)

Apoptosis (2)

Bacterial (6)

Calcium Channel (2)

Cannabinoid Receptor (3)

Cathepsin (1)

COX (4)

Cyclic GMP-AMP Synthase (1)

Drug Metabolite (1)

Endogenous Metabolite (2)

Epigenetic Reader Domain (1)

Epoxide Hydrolase (2)

FLAP (1)

Fungal (1)

GABA Receptor (2)

Glucocorticoid Receptor (1)

Glutathione S-transferase (1)

HDAC (1)

Histamine Receptor (3)

HSP (2)

Influenza Virus (1)

Interleukin Related (2)

Isotope-Labeled Compounds (1)

JAK (1)

Keap1-Nrf2 (1)

LPL Receptor (1)

LXR (1)

Melanocortin Receptor (1)

mTOR (1)

NF-κB (7)

NO Synthase (2)

P-glycoprotein (2)

p38 MAPK (1)

PARP (1)

Phosphodiesterase (PDE) (1)

Phospholipase (1)

PI3K (1)

Potassium Channel (2)

PPAR (6)

Reactive Oxygen Species (1)

ROR (1)

Sodium Channel (2)

TGF-beta/Smad (1)

Toll-like Receptor (TLR) (3)

Transmembrane Glycoprotein (1)

Trk Receptor (1)

TRP Channel (2)

VD/VDR (1)

VEGFR (1)

By Research Areas:

Cancer (17)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (6)

Inflammation/Immunology (55)

Metabolic Disease (4)

Neurological Disease (9)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-118704

P-2281	mTOR	Inflammation/Immunology Cancer
P-2281 is a mTOR inhibitor with anticancer and anti-inflammatory efficacies. P-2281 suppresses dextran sulfate sodium (DSS)-induced colitis by inhibiting T cell function and is efficacious in a murine model of human colitis .

HY-W015820

Phthalide	Bacterial	Inflammation/Immunology
Phthalide is a promising chemical scaffold with a potent anti-inflammatory efficacy. Phthalide can be used to synthesize a variety of phthalide derivatives including anti-inflammatory agent, antimicrobial, antioxidant .

HY-148940

Docosahexaenoyl glycerol	Cannabinoid Receptor	Inflammation/Immunology
Docosahexaenoyl glycerol is an analog of endocannabinoid, which stimulates the glucose uptake and exhibits anti-inflammatory efficacy .

HY-W803134

(E/Z)-SIS3 free base	TGF-beta/Smad	Inflammation/Immunology
E/Z-SIS3 free base exhibits an inhibitory efficacy against smad3, exhibits an anti-fibrotic and anti-inflammatory effect through a TGF-β/smad3 signaling pathway .

HY-107085

Talmetacin	Others	Inflammation/Immunology
Talmetacin exhibits anti-inflammatory and analgesic efficacy .

HY-110022

GW1929 hydrochloride	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential .

HY-P1615

Cenupatide	Transmembrane Glycoprotein	Cancer
Cenupatide (UPARANT) is a Urokinase-type plasminogen activator receptor (uPAR) inhibitor. Cenupatide has anti-angiogenic and *anti-inflammatory* efficacy .

HY-106365

Rofleponide	Glucocorticoid Receptor	Endocrinology
Rofleponide is a synthetic glucocorticoid that has a high affinity for rat thymic glucocorticoid receptors and has high anti-inflammatory efficacy in experimental animal models .

HY-167719

Dersalazine UR-12746 free base	Others	Inflammation/Immunology
Dersalazine (UR-12746 free base) is an inhibitor of platelet-activating factor, exhibiting intestinal anti-inflammatory activity and potential efficacy in treating ulcerative colitis.

HY-159121

sEH inhibitor-17	Epoxide Hydrolase	Neurological Disease Inflammation/Immunology
sEH inhibitor-17 (compound 4f) is an oral active soluble epoxide hydrolase (sEH) inhibitor with the IC₅₀ of 2.94 nM. sEH inhibitor-17 shows anti-inflammatory efficacy .

HY-170489

Antifungal agent 123	Bacterial Fungal Toll-like Receptor (TLR)	Infection Inflammation/Immunology
Antifungal agent 123 (Compound 4b) exhibits good affinity to the oxidoreductase of Staphylococcus aureus or the membrane protein of Candida albicans, exhibits antibacterial and antifungal activities. Antifungal agent 123 scavenges free radical, exhibits antioxidant efficacy. Antifungal agent 123 inhibits the TLR signaling pathway, and exhibits anti-inflammatory efficacy .

HY-116184

PF-05387252	Endogenous Metabolite	Inflammation/Immunology
PF-05387252 is a potent and selective IRAK4 inhibitor with the activity of inhibiting endogenous TLR signaling pathways. PF-05387252 has shown anti-inflammatory activity in experimental models and may have potential clinical application value in inhibiting psoriasis. Although PF-05387252 and its related compounds have shown anti-inflammatory effects in animal models, their efficacy in inhibiting psoriasis has not yet been verified .

HY-N8342

Rhamnazin	VEGFR	Inflammation/Immunology Cancer
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .

HY-163271

XL-126	Epigenetic Reader Domain	Inflammation/Immunology
XL-126 (Compound 33) is a potent BD1-selective BET inhibitor, with a K_d of 8.9 nM. XL-126 leads to both the preservation of platelets and potent anti-inflammatory efficacy by BD1 selectivity .

HY-P10431

Hc-CATH Sea snake cathelicidin	Bacterial	Infection Inflammation/Immunology
Hc-CATH (Sea snake cathelicidin) is an antibacterial peptide with broad-spectrum. Hc-CATH inhibits Shigella dysenteriae and Klebsiella pneumoniae with MIC of 0.16 mM-20.67 mM. Hc-CATH exhibits anti-inflammatory efficacy .

HY-118312

CAY10657	NF-κB	Inflammation/Immunology
CAY10657 is an inhibitor for NF-κB pathway. CAY10657 downregulates expressions of proinflammatory cytokine (IL-6) and chemokine (MCP-1), and thus exhibits anti-inflammatory efficacy against meningitis induced by Streptococcus suis .

HY-N0396

Harpagoside 1 Publications Verification	COX NO Synthase	Inflammation/Immunology Cancer
Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ) .

HY-167734

Pemedolac AY-30715	COX	Inflammation/Immunology
Pemedolac (AY-30715) is a potent analgesic with significant pain-relief efficacy against chemically induced and inflammatory pain in animal models. Pemedolac displays a notable separation between analgesic effects and anti-inflammatory activity, achieving effective pain relief at much lower doses than those required for anti-inflammatory or gastric irritant effects. Pemedolac also shows low ulcerogenic potential, indicating a safer profile compared to standard NSAIDs while being utilized for the treatment of neurological, skin, and musculoskeletal disorders.

HY-107561

A-943931 hydrochloride	Histamine Receptor	Inflammation/Immunology
A-943931 (Compound 10) is a histamine H₄ receptor antagonists. A-943931 has improved pharmacotropic and in vivo efficacy in models of pain and inflammation. A-943931 can be used in vivo anti-inflammatory and anti-nociception research .

HY-N12261

Benastatin B	Glutathione S-transferase Bacterial	Infection Inflammation/Immunology Cancer
Benastatin B is an inhibitor for glutathione S-transferase, that inhibits human pi class GST with an IC₅₀ of 1.10 μg/mL. Benastatin B exhibits board-spectrum antibacterial efficacy, inhibits MRSA with MIC 3.1 μg/mL. Benastatin B exhibits anti-inflammatory efficacy through inhibition of IgE mediated β-hexosaminidase release with an IC₅₀ of 79 μg/mL .

HY-143444

JAK-IN-20	JAK	Inflammation/Immunology
JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC₅₀s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo .

HY-113936

A-943931	Histamine Receptor	Neurological Disease Inflammation/Immunology
A-943931 is a potent and selective histamine H4 receptor (H4R) antagonist with pK_i values of 4.6, 3.8 nM for human and rat H4R, respectively. A-943931 shows anti-inflammatory and antinociceptive efficacy .

HY-158417

KSI-6666	LPL Receptor	Inflammation/Immunology
KSI-6666 is an orally active, competitive antagonist for sphingosine 1-phosphate receptor 1 (S1PR1), with an IC₅₀ of 6.4 nM. KSI-6666 exhibits anti-inflammatory efficacy in autoimmune encephalomyelitis model and T cell transfer colitis model .

HY-138007

SR-1903	ROR PPAR LXR	Metabolic Disease Inflammation/Immunology
SR-1903 is an inverse agonist of RORγ and PPARγ (IC₅₀ of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models .

HY-170409

BNN27	Trk Receptor Apoptosis	Neurological Disease Inflammation/Immunology
BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable .

HY-N0396R

Harpagoside (Standard)	COX NO Synthase	Inflammation/Immunology
Harpagoside (Standard) is the analytical standard of Harpagoside. This product is intended for research and analytical applications. Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ) .

HY-169420

IL-6-IN-1	Interleukin Related	Inflammation/Immunology
IL-6-IN-1 (Compound 22) inhibits the release of IL-6 with an IC₅₀ of 1.065 μM. IL-6-IN-1 exhibits anti-inflammatory efficacy in LPS (HY-D1056)-induced acute lung injury in mouse model .

HY-110151

Bengamide B	NF-κB Interleukin Related	Cancer
Bengamide B is an inhibitor for NF-κB with an IC₅₀ of 85 nM. Bengamide B inhibits LPS (HY-D1056)-induced expression of TNF-α, IL-6 and MCP-1, exhibits anti-inflammatory activity. Bengamide B exhibits antitumor efficacy (IC₅₀ for HCT-116 is 2 nM) .

HY-155611

Cathepsin C-IN-6	Cathepsin	Inflammation/Immunology
Cathepsin C-IN-6 (compound 2) is a E-64c-hydrazideas based inhibitor of cathepsin C with anti-inflammatory activity. Cathepsin C-IN-6 inhibts activation of neutrophil elastase，exhibits potential efficacy in inflammatory diseases with high neutrophil load (e.g.，chronic obstructive pulmonary disease) .

HY-113829

Valnemulin	Antibiotic Bacterial	Infection Inflammation/Immunology
Valnemulin is an orally active broad-spectrum antibiotic against Gram-negative and Gram-positive bacteria, anaerobic bacteria, Mycoplasma, and Spirochetes. Valnemulin ameliorates enteric diseases, acute polyarthritis and enzootic pneumonia in pigs . Valnemulin exhibits anti-inflammatory efficacy against lipopolysaccharide (HY-D1056)-induced lung injury .

HY-134521

Diclofenac amide	COX	Inflammation/Immunology
Diclofenac amide is a prodrug for Diclofenac sodium (HY-15037). Diclofenac amide is an orally active inhibitor for COX-1/2, that inhibits the production of prostaglandins (PG) and thromboxanes (TX). Diclofenac amide exhibits anti-inflammatory efficacy in Carrageenan (HY-125474)-induced rat paw edema model without causing gastric ulcer (300 μmol/kg) .

HY-168709

Nrf2 activator 18	Keap1-Nrf2	Inflammation/Immunology
Nrf2 activator 18 (Compound 11a) is an orally active activator for Keap1/Nrf2/HO-1 signaling pathway, that promotes the Nrf2 nuclear translocation, and enhances the antioxidant efficacy. Nrf2 activator 18 inhibits the release of IL-6 with an IC₅₀ of 4.816 μM. Nrf2 activator 18 exhibits anti-inflammatory efficacy in mouse PM2.5-induced lung injury model .

HY-163998

TLR4-IN-1	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR4-IN-1 (compound 3k) inhibits the cell viability of RAW264.7 with an IC₅₀ of 1.02 μM. TLR4-IN-1 inhibits the release of cytokine TNF-α, IL-1β and IL-6, and exhibits anti-inflammatory efficacy in rats rheumatoid arthritis models .

HY-P10839

NBD peptide	NF-κB	Inflammation/Immunology
NBD peptide inhibits NF-κB signaling pathway through inhibition of the NEMO-IKK complex combination. NBD peptide exhibits anti-inflammatory efficacy through block of pro-inflammatory cytokines production. NBD peptide exhibits immunosuppressive activity through regulation of immune cells. NBD peptide enhances its transmembrane ability by combining with cell-penetrating peptide HIV-TAT .

HY-118756

Anirolac RS37326	Endogenous Metabolite	Inflammation/Immunology
Anirolac (RS37326) is a nonsteroidal anti-inflammatory agent with analgesic activity. Anirolac showed analgesic efficacy comparable to that of naproxen in suppressing moderate or severe postpartum uterine pain. Anirolac induced significantly higher analgesia scores than placebo within 6 hours, especially at the 100 mg dose. Anirolac effectively relieved pain and showed a stronger analgesic effect than placebo in every assessment .

HY-W775346

Delta8-THC acetate Δ8-THC acetate; Delta8-tetrahydrocannabinol	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
Delta8-THC acetate (Delta8-tetrahydrocannabinol) is a psychoactive phytocannabinoid, that binds to cannabinoid receptor 1 (CB1 receptor), and exhibits anti-nausea, appetite-stimulating, and anti-inflammatory activities. Delta8-THC acetate exhibits probably neuroprotective efficacy and can be used in anti-anxiety and antidepressant research .

HY-128171

Diflapolin 1 Publications Verification	FLAP Epoxide Hydrolase	Inflammation/Immunology
Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC₅₀s?of? 30 and 170?nM, respectively, and suppressed the activity of isolated sEH (IC₅₀=20?nM) .

HY-125527A

17(R)-Resolvin D1 17(R)-RvD1; AT-RvD1	TRP Channel	Inflammation/Immunology
17R-Resolvin D1 (17R-RvD1; AT-RvD1) is an aspirin-triggered epimer of Resolvin D1, which exhibits anti-inflammatory activity in mice and human PMNs cells . 17R-Resolvin D1 specificially inhibits TRPV3 with an IC₅₀ of 398 nM and exhibits peripheral anti-nociceptive efficacy .

HY-120471

AM-0687	PI3K	Inflammation/Immunology
AM-0687 is a selective inhibitor for PI3Kδ with an IC₅₀ of 2.9 nM. AM-0687 decreases the levels of IgG and IgM specific antibodies, inhibits the anti-IgM/CD40L-induced proliferation of human B cell (IC₅₀=0.8 nM) and the phosphorylation of AKT (IC₅₀=0.7 nM), and exhibits anti-inflammatory efficacy .

HY-168734

CB2 receptor agonist 9	Cannabinoid Receptor	Inflammation/Immunology
CB2 receptor agonist 9 (Compound 33) is an orally active agonist for cannabinoid receptor 2 (CB2 receptor) with an EC₅₀ of 16.2 nM. CB2 receptor agonist 9 inhibits the expression of TNF-α, IL-1β and IL-6, exhibits anti-inflammatory efficacy in DDS (HY-116282)-induced mouse acute colitis model .

HY-B1671

(+)-Kavain	GABA Receptor Sodium Channel Calcium Channel	Neurological Disease Metabolic Disease
(+)-Kavain, a main kavalactone extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na ⁺ and Ca ²⁺ channels . (+)-Kavain is shown to bind at the α4β2δ GABA_A receptor and potentiate GABA efficacy . (+)-Kavain is used as a treatment for inflammatory diseases, its anti-inflammatory action has been widely studied .

HY-N2453

Convallatoxin	PPAR NF-κB P-glycoprotein	Inflammation/Immunology Cancer
Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .

HY-147276

Izuforant JW1601	Histamine Receptor	Inflammation/Immunology
Izuforant (JW1601) (Compound 24) is an orally active histamine H4 receptor (H4R) antagonist with an IC₅₀ of 36 nM against human H4R. Izuforant also shows binding affinity of human serotonin 3 receptor (h5-HT3R) with an IC₅₀ of 9.1 μM. Izuforant exhibits strong anti-pruritic and anti-inflammatory efficacies .

HY-135646

Eleutheroside B1	Influenza Virus	Infection Inflammation/Immunology
Eleutheroside B1, a coumarin compound, has a wide spectrum of anti-human influenza virus efficacy, with an IC₅₀ value of 64-125 µg/ml. Eleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation. Eleutheroside B1 inhibits the mRNA expression of several chemokine genes and the influenza nucleoprotein (NP) gene, and exhibits low cytotoxicity. Antiviral and anti-inflammatory activities .

HY-155458

HYDAMTIQ	PARP	Inflammation/Immunology Cancer
HYDAMTIQ is a PARP-1/2 inhibitor (IC₅₀: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more .

HY-170527

Anticancer agent 260	Reactive Oxygen Species	Neurological Disease Inflammation/Immunology Cancer
Anticancer agent 260 (Compound 3g/4d) is an orally active anticancer agent, that inhibits the proliferation of cancer cell HCT-116, MIA-PaCa2 and MDA-MB231 with IC₅₀s of 98.7, 81.0, and 77.2 µg/mL, respectively. Anticancer agent 260 exhibits promotes ulcer formation and lipid peroxidation, anti-inflammatory and analgesic efficacy .

HY-N0894A

(3R,5R)-Octahydrocurcumin (3R,5R)-Hexahydrobisdemethoxycurcumin	Drug Metabolite	Neurological Disease Inflammation/Immunology
(3R,5R)-Octahydrocurcumin (Compound 7) is gut microbial metabolite of Curcumin (HY-N0005). (3R,5R)-Octahydrocurcumin exhibits neuroprotective efficacy against Aβ25-35-induced cell damage in SH-SY5Y, and anti-inflammatory activity against LPS-stimulated mouse microglial BV-2 .

HY-B1671R

(+)-Kavain (Standard)	GABA Receptor Sodium Channel Calcium Channel	Neurological Disease Metabolic Disease
(+)-Kavain (Standard) is the analytical standard of (+)-Kavain. This product is intended for research and analytical applications. (+)-Kavain, a main kavalactone extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels . (+)-Kavain is shown to bind at the α4β2δ GABAA receptor and potentiate GABA efficacy . (+)-Kavain is used as a treatment for inflammatory diseases, its anti-inflammatory action has been widely studied .

HY-N2453R

Convallatoxin (Standard)	PPAR NF-κB P-glycoprotein	Inflammation/Immunology Cancer
Convallatoxin (Standard) is the analytical standard of Convallatoxin. This product is intended for research and analytical applications. Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .

HY-10320G

Doramapimod (GMP) BIRB 796 (GMP)	p38 MAPK	Cancer
Doramapimod GMP (BIRB 796 GMP) is an orally active inhibitor for p38 MAPK, with IC₅₀s of 38, 65, 200 and 520 nM, for p38α, p38β, p38γ, p38δ. Doramapimod exhibits cytotoxicity and antitumor activity against multiple myeloma, synergizes with multidrug resistance protein 1 (ABCB1) and aurora kinase inhibitor VX680, promoting their antitumor efficacy against oral epidermoid carcinoma and cervical cancer. Doramapimod also exhibits anti-inflammatory activity .

Cat. No.	Product Name

HY-L022M

FDA-Approved Drug Library Mini

3,102 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,102 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

Cat. No.	Product Name	Target	Research Area